TTC Oncology to Present at Biotech Showcase™ Digital 2021
CHICAGO--(BUSINESS WIRE)--TTC Oncology (“TTC” or the “Company”) CEO and CMO Arek Dudek, MD, PhD, will be participating in the Biotech Showcase virtual conference occurring January 11-15, 2021. Dr. Dudek will be providing a Company overview and update on the Company’s financing needs as well as TTC’s lead product candidate, TTC-352.
TTC-352 is a novel, first-in-class and best-in-class orally available small molecule being developed as a treatment for patients with metastatic estrogen receptor-positive (ER+) breast cancer who have failed 2 or more prior therapies. TTC-352 is a selective human ER partial agonist (ShERPA) that induces unfolded protein response leading to breast cancer cell death and acts in a similar manner as hormone therapy by modulating estrogen actions.
Breast cancer afflicts approximately 2.1 million women in the US yearly with the majority of these cases being ER+ in which the hormone estrogen promotes tumor growth. Typically, patients with ER+ breast cancer are initially treated with hormonal therapy which blocks the tumorigenic actions of natural estrogen. However, many patients are unable to tolerate hormonal therapy which leads to discontinuation of treatment. Up to half of all patients who undergo this treatment develop resistance to therapy which can lead to cancer recurrence.
TTC Oncology has completed a Phase I human clinical trial where TTC-352 was shown to have only minimal side effects. In several women participating in the trial, TTC-352 successfully treated breast tumors resistant to multiple lines of hormonal and chemotherapy treatments. The best responders from the study include:
- A 49-year-old woman with ER+, progesterone receptor-positive (PR+), HER2-breast cancer with visceral metastases. After progressing on multiple prior lines of hormonal and chemotherapies (12 total), TTC-352 induced 6% tumor shrinkage and controlled disease for 309 days with negligible toxicity
- A 77-year-old woman with ER+, PR+, HER2-breast cancer with bone metastases. After trying 16 prior lines of hormonal and chemotherapy, TTC-352 treatment resulted in stable disease for 280 days with negligible toxicity
Based on these encouraging results, TTC Oncology are planning to develop TTC-352 to be commercially indicated as a second-line therapy of ER+ breast cancer.
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry's largest gatherings and busiest weeks.
ABOUT BIOTECH SHOWCASE
Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its 13th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.
ABOUT TTC Oncology
TTC Oncology is an emerging biotechnology company founded in 2015. TTC Oncology’s mission is to develop and bring to market a novel, small-molecule therapy, TTC-352, to address the unmet needs of breast cancer patients. TTC has a license from the University of Illinois at Chicago covering the therapy. They are seeking $15 million Series A investment to initiate and complete pivotal Phase II studies, and their goal is to complete studies in 36 months.
Arek Dudek, CEO and CMO, firstname.lastname@example.org
Klara Czobor, CDO, email@example.com